SUPN - Supernus Pharmaceuticals, Inc.
| Previous Close | 48.85 |
| Open | 48.70 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 47.51 - 49.45 |
| 52 Week Range | 29.95 - 50.05 |
| Volume | 526,147 |
| Avg. Volume | 675,369 |
| Market Cap | 2.5B |
| Beta | 1.70 |
| PE Ratio (TTM) | 45.12 |
| EPS (TTM) | 1.08 |
| Earnings Date | May 7, 2018 - May 11, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 53.67 |
- Motley Fool•2 days ago
3 Top Biotech Stocks to Buy Right Now
There's good reason to consider buying shares in these biotech companies soon.
- MarketWatch•4 days ago
Harry Boxer’s biotech-stock breakouts to watch
In focus: uniQure, Supernus Pharmaceuticals and ViewRay.
Market Realist•5 days agoAnalysts’ Recommendations for AbbVie in April 2018
In April 2018, the FDA notified AbbVie (ABBV) and Neurocrine Biosciences that it would need more time to review liver function test data provided by AbbVie with its new drug application for Elagolix for the management of endometriosis-associated pain, extending its Prescription Drug User Fee Act goal date by three months to 3Q18. In 4Q17, the FDA granted Elagolix priority review. In clinical trials, Elagolix was evaluated for safety and efficacy in ~1,700 women with moderate-to-severe endometriosis-related pain.
Markit•7 days agoSee what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.
Short interest is moderate for SUPN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding SUPN totaled $776 million.
- Simply Wall St.•11 days ago
Top 3 Growth Stocks For The Month
Investors tend to look for stocks that have a strong future outlook. Why invest in something that will grow slower than the rest of the market? In terms of profitabilityRead More...
- GlobeNewswire•12 days ago
Factors of Influence in 2018, Key Indicators and Opportunity within Harmonic, Supernus Pharmaceuticals, America First Multifamily Investors, Ballard Power, ServiceSource International, and Materialise NV — New Research Emphasizes Economic Growth
NEW YORK, April 11, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Markit•13 days agoSee what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc NASDAQ NMS:SUPN
Market Realist•13 days agoHere’s What Drove Supernus Pharmaceuticals Stock in March 2018
Supernus Pharmaceuticals (SUPN) stock has risen 18.2%, from $38.75 on March 1, 2018, to $45.80 on March 29, 2018. In its 2017 results announced on February 28, 2018, the company focused on developing and commercializing drugs targeted at treating central nervous system diseases. It reported a 41% year-over-year (or YoY) growth in fiscal 2017 revenues, which were about $300 million. It also reported earnings before income tax of around $100 million in 2017, which is a YoY rise of 100%. ...
- Thomson Reuters StreetEvents•24 days ago
Edited Transcript of SUPN earnings conference call or presentation 28-Feb-18 2:00pm GMT
Q4 2017 Supernus Pharmaceuticals Inc Earnings Call
- American City Business Journals•last month
Supernus getting Maryland incentives in HQ relocation, plans to add 160 jobs
Now we know Maryland is helping out to the tune of more than $1.7 million. Maryland Gov. Larry Hogan announced Wednesday the state will provide $800,000 loan through the Maryland Economic Development Assistance Authority and Fund to assist with the move. Montgomery County is providing a $500,000 conditional grant through its Economic Development Fund, and Gaithersburg is providing a grant up to $400,000 through its Economic Development Opportunity Fund.
- GlobeNewswire•last month
Supernus Announces Pricing of $350 Million Private Offering of 0.625% Convertible Senior Notes
ROCKVILLE, Md., March 15, 2018-- Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, ...
- American City Business Journals•last month
Supernus getting Maryland incentives in HQ relocation, plans to add 160 jobs
The company is moving from Rockville to Gaithersburg.
- GlobeNewswire•last month
Research Report Identifies Supernus Pharmaceuticals, Celestica, Global Blood Therapeutics, BioTime, CyberArk Software, and Tivity Health, Inc. with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, March 14, 2018--. In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Markit•last monthSee what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.
Short interest is moderate for SUPN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
- GlobeNewswire•last month
Supernus Announces Proposed Private Offering of $350 Million of Convertible Senior Notes
ROCKVILLE, Md., March 13, 2018-- Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, ...
- American City Business Journals•2 months ago
Supernus Pharmaceuticals inks deal for new, expanded headquarters
After a year of surging growth, Supernus Pharmaceuticals Inc. is building out a new home double its current size. The Rockville biotech, which specializes in creating therapies for central nervous system diseases, is moving its headquarters to the Firstfield Life Science Cluster at 700 Quince Orchard Road in Gaithersburg, leasing approximately 119,000 square feet, according to a filing with the Securities and Exchange Commission. It's nearly 8 miles north on Interstate 270 from its current digs, at 1550 E. Gude Drive, where it occupies 44,500 square feet of laboratory and office space.
- GlobeNewswire•2 months ago
Supernus to Present at the 2018 Cowen Health Care Conference
ROCKVILLE, Md., March 06, 2018-- Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, ...
- GuruFocus.com•2 months ago
Supernus Pharmaceuticals Inc (SUPN) Files 10-K for the Fiscal Year Ended on December 31, 2017
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
- ACCESSWIRE•2 months ago
Supernus Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 28, 2018, at 9:00 ...
- Associated Press•2 months ago
Supernus beats Street 4Q forecasts
On a per-share basis, the Rockville, Maryland-based company said it had profit of 26 cents. Earnings, adjusted for pretax expenses, came to 44 cents per share. The results beat Wall Street expectations. ...
- GlobeNewswire•2 months ago
Supernus Announces Record Full Year 2017 Financial Results, Exceeding Operating Earnings Guidance
Fourth quarter 2017 total revenue of $88.4 million, a 42% increase over 2016, and fourth quarter 2017 net product sales of $86.3 million, a 41% increase over 2016. Fourth quarter 2017 operating earnings ...
- Benzinga•2 months ago
Supernus Pharmaceuticals Q4 Earnings Preview
On Tuesday, Supernus Pharmaceuticals (NASDAQ: SUPN ) will release its latest earnings report. Decipher the announcement with Benzinga's help. Earnings and Revenue Supernus Pharmaceuticals EPS will likely ...
- Simply Wall St.•2 months ago
Top Growth Stocks To Buy
Why invest in a stock whose growth outlook that lags behind the market? Investors looking for companies with extraordinary future prospects in terms of profitability and returns should look atRead More...
Markit•2 months agoSee what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.
Short interest is moderate for SUPN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $664 million over the last one-month into ETFs that hold SUPN are among the lowest of the last year and appear to be slowing.
- GlobeNewswire•2 months ago
Supernus to Host Fourth Quarter and Full Year 2017 Earnings Conference Call
ROCKVILLE, Md., Feb. 12, 2018-- Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, ...
